PANGYO, South Korea--(BUSINESS WIRE)--CHA Medical & Bio Group officially began construction of its Cell Gene Biobank (CGB) facility in Pangyo, South Korea. Investing over $250 million in the project, ...

The largest shareholder of Kakao Healthcare, a subsidiary of Kakao, will change to CHA CareS of CHA Bio Group. Kakao Healthcare is currently a 100% subsidiary of Kakao, but through Kakao's sale of ...

CHA Bio Group will showcase its cell and gene therapy capabilities in the annual BIO International Convention 2024 (BIO USA), the world’s largest trade show in the biotechnology and pharmaceutical ...

CHA Bio Group signed a memorandum of understanding with U.S.-based Cambridge Innovation Center (CIC) to establish an open innovation center focused on research and innovation within currently-building ...

Ground was broken Wednesday for a cell and gene treatment manufacturing facility in Pangyo, Gyeonggi, which is being built by CHA Medical & Bio Group. The 10-story building with four basement floors ...

EPS Surged to 1.27 HK Cents with a Three-year CAGR of 43.1%Robust Revenue Growth Driven by Strong Demand for Bogutai® and Omnichannel Strategy (28 August 2025 – Hong Kong) A fully integrated ...

SAN DIEGO, Oct. 5 /PRNewswire/ -- Stemedica International, S.A., ("Stemedica"), a wholly owned subsidiary of Stemedica Cell Technologies, Inc., announced the signing of an agreement to form a joint ...

Cha Bio Group, one of South Korea's largest biotechnology and healthcare companies, will acquire a minority stake in Kakao Healthcare as part of a share-swap agreement with its parent firm, Kakao Corp ...